Fibrous Dysplasia of Bone: Clinical Trials

9 trials for Fibrous Dysplasia of Bone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 active not recruiting. 9 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 8, Active not recruiting 1
Phase 31Completed 1

Follow Fibrous Dysplasia of Bone: new trials by email Literature Review of Fibrous Dysplasia of Bone trials Research Report on Fibrous Dysplasia of Bone

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
Burosumab - Fibrous Dysplasia Of Bone
Phase 2CompletedNational Institute of Dental and Craniofacial Research (NIDCR)122022-12-072026-02-02
Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
denosumab - Fibrous Dysplasia
Phase 2CompletedNational Institute of Dental and Craniofacial Research (NIDCR)152022-10-122026-01-20
Denosumab Treatment for Fibrous Dysplasia
Denosumab - Bone Diseases, Pain
Phase 2Active not recruitingNational Institute of Dental and Craniofacial Research (NIDCR)92019-06-132022-02-18
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE
Tocilizumab, Placebo - Fibrous Dysplasia of Bone
Phase 2CompletedHospices Civils de Lyon192013-05-052025-10-02
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
risedronate, placebo - Fibrous Dysplasia of Bone
Phase 2 / Phase 3CompletedInstitut National de la Santé Et de la Recherche Médicale, France802007-07-222021-08-30
Faslodex in McCune-Albright Syndrome
Fulvestrant - Puberty, Precocious, McCune-Albright Syndrome
Phase 2CompletedAstraZeneca302006-01-312024-03-05
Arimidex in McCune Albright Syndrome
Arimidex 1 mg - McCune-Albright Syndrome
Phase 2CompletedAstraZeneca402002-08-012015-09-01
Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
Fosamax (Alendronate) - Polyostotic Fibrous Dysplasia
Phase 2CompletedNational Institute of Dental and Craniofacial Research (NIDCR)401998-08-242017-07-02
Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty
Testolactone - Polyostotic Fibrous Dysplasia, Precocious Puberty
Phase 2CompletedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1001982-10-012008-03-04

Narrower conditions

Fibrous Dysplasia, Polyostotic (7)  ·  Puberty, Precocious (2)  ·  Bone Diseases (1)  ·  Bone Diseases, Metabolic (1)  ·  Osteomalacia (1)  ·  Pain (1)  ·  Rickets (1)  ·  Uterine Hemorrhage (1)

Broader conditions

Bone Diseases, Developmental (9)  ·  Musculoskeletal Diseases (9)  ·  Osteochondrodysplasias (9)  ·  Bone Diseases (8)  ·  Endocrine System Diseases (2)  ·  Gonadal Disorders (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Avitaminosis (1)  ·  Calcium Metabolism Disorders (1)  ·  Deficiency Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)

Interventions

Denosumab (2)  ·  Alendronate (1)  ·  Anastrozole (1)  ·  Fulvestrant (1)  ·  Risedronic Acid (1)  ·  Testolactone (1)  ·  burosumab (1)  ·  tocilizumab (1)

Sponsors

National Institute of Dental and Craniofacial Research (NIDCR) (4)  ·  AstraZeneca (2)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Hospices Civils de Lyon (1)  ·  Institut National de la Santé Et de la Recherche Médicale, France (1)

Countries

United States (6)  ·  France (4)  ·  Germany (3)  ·  Italy (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Netherlands (1)  ·  Russia (1)

Top investigators

Alison M Boyce, M.D. (3)

Results publications

PMID 22999294, PMID 25033066, PMID 35104665, PMID 36812441, PMID 38378678, PMID 41534675

NIH funding

2005 (1)